http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010022581-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb9d3d07fa74cc112607e88a18f14f07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fa634debd69245f47f9331737d2a689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9467f092b9d25b1a223fbd6965f18d2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93ec31e4e6ff26f66c15226b32e65c47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cb1e69e05f4dc9a22403b97079c6ec4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06
filingDate 2009-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0947389371b860c9de11f181d022e2fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddde21b90306add2c00a3bfb74a0ea6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85d2215363490204a37535fc3eafcbff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c8439b43cd73716b52625165f432c01
publicationDate 2010-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2010022581-A1
titleOfInvention Medical composition for treating hyperuricemia and the use thereof
abstract The present invention provides a medical composition for treating hyperuricemia or correlative diseases thereof, including febuxotat or derivatives thereof, probenecid and pharmaceutically acceptable carriers, wherein the weight ratio of febuxotat or derivatives thereof, probenecid and pharmaceutically acceptable carriers is 1:10~200:0.5~100. The present invention also provides the use of the medical composition and a method for treating hyperuricemia or correlative diseases thereof.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113995771-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112957318-A
priorityDate 2008-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395793
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4911

Total number of triples: 32.